# UK Allergy Immunotherapy Market > UK Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) and By Patient Type (Pediatric, Adult, Geriatric) - Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 9.43% - **2018:** $ 199.5 Million - **2024:** $ 217.91 Million - **2035:** $ 587.28 Million - **Key Players:** Allergopharma (DE), ALK-Abello (DK), Merck KGaA (DE), Stallergenes Greer (GB), Aimmune Therapeutics (US), Boehringer Ingelheim (DE), Novartis (CH), Sanofi (FR), Bayer (DE) **Report ID:** MRFR/HC/54526-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-allergy-immunotherapy-market-56292 --- ## Market Summary **UK Allergy Immunotherapy Market Overview****:** **As per MRFR analysis, the UK Allergy Immunotherapy Market Size was estimated at 199.5 (USD Million) in 2023. The UK Allergy Immunotherapy Market Industry is expected to grow from 214.12(USD Million) in 2024 to 530.62 (USD Million) by 2035. The UK Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 8.6% during the forecast period (2025 - 2035).** **Key UK Allergy Immunotherapy Market Trends Highlighted** Growth in the UK Allergy Immunotherapy Market is being fueled by a number of critical market drivers. An increased demand for effective treatment options has been prompted by the increasing prevalence of allergic conditions, including hay fever and food allergies. In addition, the increasing recognition of the advantages of immunotherapy in comparison to conventional medication is having a positive impact on both patients and healthcare providers. Research and technological advancements have facilitated this transition, resulting in enhanced patient outcomes and treatment methodologies. There are numerous opportunities to investigate, including the integration of technology, such as mobile applications, to more effectively monitor and manage allergies and the expansion of treatment options for specific allergens. Personalized medicine is becoming a more prominent focus of the National Health Service (NHS), which is in perfect harmony with the potential of immunotherapy to offer patients customized solutions. Furthermore, advancements in delivery systems and innovative therapies are being facilitated by the increasing collaborations between academic institutions and industry actors. A substantial shift toward digital health solutions has been observed in recent trends as an increasing number of patients seek to manage their allergies online.Digital innovations in healthcare have been encouraged by the UK government, as evidenced by initiatives that are designed to improve patient access to digital tools for allergy management. As an outcome, the integration of healthcare and technology is facilitating the development of a more effective and user-friendly allergy management system. Furthermore, the overall adoption of immunotherapy treatments in the UK is further facilitated by the emphasis on patient education and awareness campaigns. Ultimately, these market trends demonstrate a responsive landscape that is adjusting to the requirements of patients and simultaneously addressing the increasing burden of allergies in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Allergy Immunotherapy Market Drivers** Increasing Prevalence of Allergies in the UK The rising prevalence of various allergies, particularly respiratory allergies such as seasonal allergic rhinitis and allergic asthma, is a significant driver for the UK Allergy Immunotherapy Market Industry. According to the National Health Service (NHS), approximately 44% of adults in the UK reported having at least one allergy as of 2021, which is a notable increase from previous years. This trend is expected to continue, contributing to the growing demand for immunotherapy treatments.The Health Survey for England indicates that about 3.2 million people have asthma in the UK, highlighting a substantial patient population that could benefit from immunotherapy. The increased awareness regarding allergy management and the effectiveness of immunotherapy are compelling factors encouraging both practitioners and patients to consider this treatment option, further driving market growth. Advancements in Immunotherapy Techniques Technological advancements in immunotherapy are helping to enhance the effectiveness of allergy treatments, making this a crucial driver for the UK Allergy Immunotherapy Market Industry. Innovations such as sublingual immunotherapy have simplified treatment regimens and improved patient adherence. The UK has seen significant investment in Research and Development by major pharmaceutical manufacturers like GlaxoSmithKline and AstraZeneca, who are pioneering new therapies that target specific allergic responses.Furthermore, clinical trials conducted by institutions such as the University of Manchester demonstrate promising outcomes for new immunotherapeutic approaches. This progress not only boosts confidence among healthcare providers and patients but also positions the UK as a leader in allergy treatment options. Government Initiatives and Support for Allergy Treatment Government initiatives aimed at enhancing healthcare services and treatments for allergic conditions are playing a vital role in the expansion of the UK Allergy Immunotherapy Market Industry. Recent policies have underscored the necessity of improving allergy management, with the Department of Health and Social Care promoting guidelines for the diagnosis and treatment of allergies. According to the UK House of Commons, funding for allergy services has increased, ensuring that more patients gain access to appropriate treatments, including immunotherapy options.These initiatives help strengthen healthcare infrastructure and improve patient outcomes, which collectively drive market growth. Growing Awareness and Education on Allergies Increasing awareness of allergies and the benefits of immunotherapy is another significant factor influencing the UK Allergy Immunotherapy Market Industry. Campaigns conducted by organizations like Allergy UK have played a crucial role in educating the public about allergy management and available treatment options. Recent surveys indicate that around 70% of adults in the UK are now aware of immunotherapy as a viable treatment for long-term allergy relief, compared to just 50% five years ago.The enhanced understanding of the long-term benefits of immunotherapy treatments, combined with active community engagement, is driving patients to seek these therapies, thereby facilitating market expansion. **UK Allergy Immunotherapy Market Segment Insights****:** **Allergy Immunotherapy Market Type Insights****** **** The UK Allergy Immunotherapy Market has been segmented into three key types, namely Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy, each playing a crucial role in addressing the growing prevalence of allergic conditions in the country. Subcutaneous Immunotherapy involves the administration of allergen extracts through injections and is recognized for its extensive use and efficacy in treating various allergic reactions like hay fever and allergic rhinitis. This method is generally considered a traditional approach, often deemed more conventional, especially among specialists, due to years of practice and established protocols.On the other hand, Sublingual Immunotherapy has gained traction because it offers a more patient-friendly delivery system, allowing individuals to take medications under their tongue. This can enhance patient compliance and is perceived as less invasive compared to injections, which can be a significant factor for patients who experience anxiety towards needles. The increasing preference for self-administration in home settings bolsters the appeal of sublingual therapies, making it a growing segment of the market. Meanwhile, Oral Immunotherapy has emerged as a promising alternative, particularly for food allergies.It involves giving gradually increasing amounts of allergenic food in a controlled manner to build tolerance, which addresses a significant unmet need in managing food-related allergies. The UK, with its increasing food allergy prevalence, is particularly observing innovations in this area. Each of these types offers distinct benefits and may appeal to different patient populations based on their needs and preferences. The UK Allergy Immunotherapy Market is expected to grow as advancements in technology and improved formulations drive better treatment outcomes across these segments.Overall, the diversity within the Type segmentation reflects the market's adaptability to evolving patient requirements and contributes to a well-rounded approach to allergy management. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Allergy Immunotherapy Market Product Insights****** **** The UK Allergy Immunotherapy Market is characterized by a diverse array of products that significantly contribute to addressing allergic conditions across the population. The Product segment encompasses essential categories such as Allergen Extracts, Conventional Immunotherapy, and Biologics, each playing a critical role in managing allergies. Allergen Extracts are vital as they enable personalized treatment plans tailored to the specific allergens affecting patients, making them a preferred choice among practitioners. Conventional Immunotherapy, known for its established efficacy, continues to dominate the market due to its long history of use, offering patients a reliable long-term solution for their allergies.In recent years, Biologics have gained attention for their innovative mechanisms, targeting specific pathways in allergic responses, which may present new opportunities for patients with challenging conditions. As allergy prevalence continues to rise in the UK, the demand for effective, sustainable, and accessible allergy treatments further drives growth and innovation in this market segment. The integration of research, technological advancements, and patient-centered approaches within these categories highlights their importance and role in improving the quality of life for many individuals affected by allergies in the region. **Allergy Immunotherapy Market Indication Insights****** **** The UK Allergy Immunotherapy Market is experiencing notable expansion, particularly within the Indication segment, which encompasses Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Allergic Rhinitis holds a prominent position as one of the most prevalent allergic conditions in the UK, affecting a significant portion of the population, especially during pollen seasons. Allergic Asthma is another critical area, as increased pollution levels and climate change have contributed to rising cases, making effective immunotherapy vital for management.Atopic Dermatitis is increasingly recognized for its long-term implications on quality of life, driving demand for targeted therapies. Food Allergies, particularly in children, have garnered attention due to their life-threatening potential; therefore, advancements in immunotherapy to safely desensitize patients are essential. The growing awareness regarding these conditions, along with an emphasis on personalized treatment approaches, is fueling the overall growth in the UK Allergy Immunotherapy Market, making this segment crucial for addressing public health challenges related to allergies. **Allergy Immunotherapy Market Patient Type Insights****** **** The UK Allergy Immunotherapy Market, categorized by Patient Type, plays a crucial role in addressing the diverse needs of allergy sufferers across different age groups. This segment encompasses Pediatric, Adult, and Geriatric patients, each presenting unique characteristics and treatment requirements. Pediatric patients are particularly significant as early interventions can fundamentally alter the trajectory of allergy management and have been linked to improved long-term outcomes. Adult patients often face more complex allergen exposure due to lifestyle factors and are likely to seek immunotherapy, which is pivotal for their quality of life.Meanwhile, the Geriatric population is growing and is particularly vulnerable to allergic reactions that could complicate pre-existing health conditions, making targeted treatments essential. The increasing prevalence of allergies in the UK, combined with a rising awareness of immunotherapy benefits, highlights the urgency and relevance of this segment. The market growth within these demographics indicates a pressing need for tailored therapeutic approaches to effectively manage allergies, reflecting broader healthcare trends and population health priorities in the UK. **UK Allergy Immunotherapy Market Key Players and Competitive Insights****:** The UK Allergy Immunotherapy Market is experiencing significant growth driven by an increase in the prevalence of allergic conditions and a growing awareness among patients regarding allergy treatments. The competitive landscape is progressively evolving, characterized by the presence of established pharmaceutical companies and innovative biotechnology firms. These players are actively engaged in research and development to enhance their portfolios of immunotherapeutic products aimed at addressing various types of allergies, such as pollen, dust mites, and animal dander. The entry of new companies offering alternative therapies, combined with the increasing adoption of personalized medicine, has also intensified the competition in this sector. Companies are now focused on expanding their product offerings, enhancing distribution channels, and pursuing partnerships to leverage their capabilities in this niche market, thus making the UK one of the more competitive regions for allergy immunotherapy.Stallergenes Greer stands out in the UK Allergy Immunotherapy Market through its robust portfolio and strategic approach. The company is recognized for its cutting-edge allergen immunotherapy products that cater to various allergic conditions, primarily through sublingual and injectable forms. Stallergenes Greer has gained a strong market presence by investing in clinical research and participating in collaboration initiatives with healthcare practitioners to foster greater awareness of allergy treatments among patients. The company’s commitment to quality and adherence to regulatory standards has earned it a reputable standing among healthcare providers in the UK. Additionally, Stallergenes Greer has focused on leveraging its technological advancements to offer patient-centric solutions that enhance treatment adherence and efficacy, further solidifying its competitive advantage in a diverse and fast-evolving market.Anergis has positioned itself as an innovative player in the UK Allergy Immunotherapy Market, leveraging its pioneering work on grass pollen immunotherapy. The company is primarily known for its sublingual immunotherapy products, which offer a convenient and effective treatment solution for patients suffering from seasonal allergies. Anergis boasts a strong pipeline of products, emphasizing its commitment to advancing the field of immunotherapy. Its strategic partnerships and collaborations with other research institutions empower Anergis to accelerate its development processes while driving innovations that address unmet medical needs. Additionally, Anergis has pursued acquisition strategies to enhance its capabilities and broaden its market reach in the UK, focusing on expanding its product lines and establishing a solid foothold in the growing allergy treatment landscape. The company’s strengths lie in its specialized expertise, commitment to research-driven solutions, and an emphasis on delivering high-quality therapeutic options to patients, ensuring it remains competitive in this dynamic marketplace. **Key Companies in the UK Allergy Immunotherapy Market Include:** Stallergenes Greer Anergis Allergy Therapeutics Hugo Boss Boehringer Ingelheim Mylan Meda Pharmaceutical Sanofi Hollister Incorporated Ionis Pharmaceuticals DBV Technologies TheraTogs Allergenis Circassia ALK Abello **UK Allergy Immunotherapy Market Industry Developments** _Recent developments in the UK Allergy Immunotherapy Market have shown a notable increase in collaboration and innovation among key players, including Stallergenes Greer, Allergy Therapeutics, and Boehringer Ingelheim. In September 2023, Stallergenes Greer announced an initiative aimed at expanding their sublingual immunotherapy offerings to improve accessibility for patients with allergic rhinitis. Meanwhile, Allergy Therapeutics launched a new clinical trial for their grass pollen allergy treatment, reflecting the growing focus on research and development in the sector. The market also remains dynamic__,__with significant mergers and acquisition activities. In August 2023, Anergis completed a strategic acquisition of Allergenis aimed at enhancing their immunotherapy capabilities within the UK. The market is valued at approximately 183 million as of 2023, with a projected annual growth rate fueled by increasing allergy prevalence in the UK. Moreover, regulatory bodies have been actively collaborating with industry leaders to facilitate the development of novel therapies. Over the past few years, the UK has witnessed substantial investments into allergy immunotherapy, strengthening its position as a key market in Europe, especially with a growing demand for personalized treatment options._ **UK Allergy Immunotherapy Market Segmentation Insights** **Allergy Immunotherapy Market Type****Outlook** **Subcutaneous Immunotherapy** **Sublingual Immunotherapy** **Oral Immunotherapy** **Allergy Immunotherapy Market Product****Outlook** **Allergen Extracts** **Conventional Immunotherapy** **Biologics** **Allergy Immunotherapy Market Indication****Outlook** **Allergic Rhinitis** **Allergic Asthma** **Atopic Dermatitis** **Food Allergies** **Allergy Immunotherapy Market Patient Type****Outlook** **Pediatric** **Adult** **Geriatric** **** ## Market Drivers ### Rising Awareness of Allergies The increasing awareness of allergies among the UK population is a notable driver for the UK [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. As more individuals recognize the symptoms and implications of allergies, there is a growing demand for effective treatment options. Public health campaigns and educational initiatives have contributed to this awareness, leading to a rise in consultations with healthcare professionals. Consequently, this heightened awareness is likely to result in an increase in the number of patients seeking immunotherapy treatments. According to recent data, approximately 44% of adults in the UK report experiencing allergy symptoms, which underscores the potential market for immunotherapy solutions. This trend suggests that as awareness continues to grow, the UK Allergy Immunotherapy Market may experience significant expansion. ### Rising Healthcare Expenditure The rising healthcare expenditure in the UK is a significant driver for the UK Allergy Immunotherapy Market. As the government allocates more resources to healthcare, there is an increased focus on allergy management and treatment options. This trend is reflected in the growing budgets for allergy services within the National Health Service (NHS), which has recognized the need for effective immunotherapy solutions. With healthcare spending projected to rise by approximately 4% annually, there is a strong potential for the expansion of immunotherapy services. This increase in funding allows for better access to treatments and enhances the overall quality of care for patients suffering from allergies. Consequently, the UK Allergy Immunotherapy Market is poised for growth as healthcare expenditure continues to rise. ### Supportive Regulatory Environment A supportive regulatory environment is a key driver for the UK Allergy Immunotherapy Market. The UK government has established frameworks that facilitate the approval and commercialization of new immunotherapy products. Regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), are actively working to streamline the approval process for allergy treatments. This proactive approach encourages pharmaceutical companies to invest in the development of new therapies, knowing that there is a clear pathway to market. Furthermore, the UK has implemented guidelines that promote the safe and effective use of immunotherapy, which enhances patient confidence in these treatments. As a result, the UK Allergy Immunotherapy Market is likely to benefit from an influx of innovative products and increased patient access to effective therapies. ### Growing Demand for Personalized Medicine The trend towards personalized medicine is significantly influencing the UK Allergy Immunotherapy Market. Patients are increasingly seeking treatments tailored to their specific allergy profiles, which has led to a shift in how immunotherapy is administered. This demand for personalized approaches is prompting healthcare providers to adopt more sophisticated diagnostic tools and treatment plans. The UK has seen a rise in the use of genetic testing and biomarker identification to customize immunotherapy regimens. As a result, the market is expected to expand as more patients opt for personalized immunotherapy solutions that promise better outcomes. This shift not only enhances patient satisfaction but also positions the UK Allergy Immunotherapy Market as a leader in innovative treatment methodologies. ### Increased Investment in Research and Development Investment in research and development (R&D) within the UK Allergy Immunotherapy Market is a critical driver of growth. Pharmaceutical companies and research institutions are increasingly focusing on developing innovative immunotherapy treatments that are more effective and have fewer side effects. This investment is supported by government initiatives aimed at fostering innovation in healthcare. For instance, the UK government has allocated substantial funding to allergy research, which has led to advancements in personalized immunotherapy approaches. The market is projected to grow at a compound annual growth rate (CAGR) of around 10% over the next five years, driven by these R&D efforts. As new therapies emerge, the UK Allergy Immunotherapy Market is likely to attract more patients seeking cutting-edge treatment options. ## Future Outlook The UK Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising consumer awareness. **New opportunities:** - Expansion of personalized immunotherapy solutions for specific allergens. Development of mobile health applications for patient monitoring and engagement. Investment in automated production technologies for allergen extracts. By 2035, the market is expected to be robust, driven by innovation and increased accessibility. ## Segment Insights ### By Indication: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing) In the UK Allergy Immunotherapy Market, [Allergic Rhinitis](https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547) stands as the largest segment, commanding a significant share due to the increasing prevalence of pollen and dust allergies. Following closely is Allergic Asthma, which is rapidly gaining traction as more individuals are diagnosed, driven by environmental factors and an enhanced awareness of asthma management. Atopic Dermatitis and Food Allergies are also present; however, they currently hold a smaller portion of the market share. The growth trends in this market segment are primarily influenced by rising allergic conditions in the UK population, with allergic rhinitis reflecting the highest demand for treatment options. Additionally, the proliferation of awareness campaigns and advancements in immunotherapy are propelling the expansion of the Allergic Asthma segment. Continuous research and development efforts to improve treatment efficacy further augment growth prospects across these indications. Allergic Rhinitis (Dominant) vs. Food Allergies (Emerging) Allergic Rhinitis represents the dominant force in the UK Allergy Immunotherapy Market, primarily attributed to seasonal changes that exacerbate symptoms and the high incidence of pollen allergies among the population. This segment benefits greatly from effective marketing strategies and an established range of treatment options that appeal to patients seeking relief from symptoms. In contrast, Food Allergies emerge as a rising segment, as awareness of food-related allergies increases among consumers and healthcare professionals. This growing recognition is catalyzed by the rising incidence of food allergies, particularly among children. Innovations in allergen immunotherapy specific to food allergies are poised to capture market interest, making it a field to watch as consumer demand continues to evolve. ### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing) In the UK Allergy Immunotherapy Market, Subcutaneous Immunotherapy leads in market share, capturing the majority of the segment due to its long-standing approval and established efficacy among patients. On the other hand, Sublingual Immunotherapy is rapidly gaining traction as the preferred choice among consumers seeking convenience and ease of administration, leading to a notable increase in its market share growth. This divergence in market positioning highlights the differing preferences within the allergy treatment landscape. The growth trends observed in the UK market indicate a significant shift towards personalized treatment options, with Sublingual Immunotherapy emerging as a popular choice driven by increasing patient awareness and demand for non-invasive solutions. Additionally, advances in technology and product formulation are expanding the reach of Sublingual options, attracting healthcare providers and patients alike. This trend points to a future where the flexibility and accessibility of allergy treatments command greater market attention. Subcutaneous Immunotherapy (Dominant) vs. Oral Immunotherapy (Emerging) Subcutaneous Immunotherapy stands as a dominant segment in the UK Allergy Immunotherapy Market, favored for its established efficacy through intradermal injections that facilitate a robust immune response. It has become a standard in treating various allergies, offering patients proven long-term relief. Conversely, Oral Immunotherapy is considered an emerging option, capitalizing on its potential to simplify treatment regimens by delivering allergens in capsule form. This method is particularly appealing for patients seeking less invasive methods and greater convenience. The ongoing research and development in Oral Immunotherapy formulations are likely to enhance patient compliance, setting the stage for substantial growth as it attracts attention from both patients and healthcare providers. ### By Administration Route: Injection (Largest) vs. Sublingual (Fastest-Growing) In the UK Allergy Immunotherapy Market, the administration route segment has diverse options, among which injections hold a significant market share, making them the largest segment. Due to their well-established efficacy, injections are preferred by many healthcare providers. In contrast, sublingual immunotherapy, although currently smaller compared to injections, is rapidly gaining traction, capturing attention for its convenience and ease of administration, particularly appealing to patients who prefer non-invasive treatments. Recent trends indicate a shift towards patient-centric approaches, propelling sublingual immunotherapy's growth. Factors such as the increasing prevalence of allergic conditions and rising consumer awareness about alternative treatments are vital drivers. Furthermore, advancements in delivery technologies are enhancing the appeal of these routes, positioning sublingual immunotherapy as a promising option for a broader patient demographic, thereby establishing it as the fastest-growing segment in the market. Injection (Dominant) vs. Sublingual (Emerging) The injection administration route remains the dominant force in the UK Allergy Immunotherapy Market, favored for its established history and reliability in delivering immunotherapy. Patients typically experience rapid allergen desensitization, leading to long-term relief from allergic symptoms. Injection therapy, while effective, often involves regular clinic visits, which may prove inconvenient for patients. In contrast, sublingual immunotherapy is emerging as a strong competitor, characterized by its ease of use as patients can administer it at home. This versatility appeals to a growing consumer base, especially those seeking less invasive options. As patient preferences shift, and due to its growing recognition, sublingual immunotherapy is likely to carve out a more significant share of the market, driven by consumer demand for convenience. ### By Patient Age Group: Pediatric (Largest) vs. Adult (Fastest-Growing) In the UK Allergy Immunotherapy Market, the distribution of market share among patient age groups reveals that the Pediatric segment holds the largest share, indicating the significant focus on addressing allergies in younger populations. The Adult segment, while not the largest, is rapidly gaining traction, particularly as awareness of adult allergies continues to rise and treatment options expand. The Geriatric and Adolescent segments also contribute to the market but represent a smaller portion of the overall share. Pediatric (Dominant) vs. Adult (Emerging) The Pediatric segment is characterized by a strong emphasis on early intervention and preventive care, making it a dominant player in the market. With increasing incidence of allergies among children and an expanding range of immunotherapy options, this segment continues to thrive. In contrast, the Adult segment is emerging as a vital market player due to rising allergy awareness and the growth of personalized treatment options. This shift is further driven by lifestyle changes, environmental factors, and the aging population, which collectively enhance the demand for effective allergy management among adults. ## Competitive Benchmarking The UK Allergy Immunotherapy Market is characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as ALK-Abello (DK), Stallergenes Greer (GB), and Merck KGaA (DE) are strategically positioned to leverage innovation and partnerships to enhance their market presence. ALK-Abello (DK) focuses on expanding its product portfolio through research and development, while Stallergenes Greer (GB) emphasizes regional partnerships to strengthen its distribution channels. Merck KGaA (DE) appears to be investing in digital transformation initiatives to optimize patient engagement and streamline operations, collectively shaping a competitive environment that prioritizes innovation and accessibility. The market structure is moderately fragmented, with several players vying for market share through localized manufacturing and supply chain optimization. This fragmentation allows for a diverse range of products and services, catering to various patient needs. The collective influence of key players fosters a competitive atmosphere where collaboration and strategic alliances are essential for growth and sustainability. In January 2026, Stallergenes Greer (GB) announced a strategic partnership with a leading UK healthcare provider to enhance access to its immunotherapy products. This collaboration is expected to facilitate better patient outcomes by integrating immunotherapy into standard care practices, thereby expanding the company's reach and reinforcing its commitment to improving allergy management. In December 2025, ALK-Abello (DK) launched a new digital platform aimed at improving patient education and adherence to immunotherapy regimens. This initiative is significant as it not only enhances patient engagement but also positions the company as a leader in utilizing technology to support treatment adherence, which is crucial for the success of immunotherapy. In November 2025, Merck KGaA (DE) unveiled a new line of sublingual immunotherapy products designed to address specific regional allergies prevalent in the UK. This product launch reflects the company's strategy to tailor its offerings to local market needs, potentially increasing its competitive edge by providing targeted solutions that resonate with patients and healthcare providers alike. As of February 2026, current trends in the UK Allergy Immunotherapy Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and reliable supply chains, underscoring the importance of adaptability in a rapidly changing market. ## Recent News & Developments _Recent developments in the UK Allergy Immunotherapy Market have shown a notable increase in collaboration and innovation among key players, including Stallergenes Greer, Allergy Therapeutics, and Boehringer Ingelheim. In September 2023, Stallergenes Greer announced an initiative aimed at expanding their sublingual immunotherapy offerings to improve accessibility for patients with allergic rhinitis. Meanwhile, Allergy Therapeutics launched a new clinical trial for their grass pollen allergy treatment, reflecting the growing focus on research and development in the sector. The market also remains dynamic__,__with significant mergers and acquisition activities. In August 2023, Anergis completed a strategic acquisition of Allergenis aimed at enhancing their immunotherapy capabilities within the UK. The market is valued at approximately 183 million as of 2023, with a projected annual growth rate fueled by increasing allergy prevalence in the UK. Moreover, regulatory bodies have been actively collaborating with industry leaders to facilitate the development of novel therapies. Over the past few years, the UK has witnessed substantial investments into allergy immunotherapy, strengthening its position as a key market in Europe, especially with a growing demand for personalized treatment options._ ## Report Scope Report Scope: | Report Attribute/Metric Source: | Details | | --- | --- | | MARKET SIZE 2018 | 199.5(USD Million) | | MARKET SIZE 2024 | 214.12(USD Million) | | MARKET SIZE 2035 | 530.62(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.6% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | MARKET FORECAST PERIOD | 2025 - 2035 | | HISTORICAL DATA | 2019 - 2024 | | MARKET FORECAST UNITS | USD Million | | KEY COMPANIES PROFILED | Stallergenes Greer, Anergis, Allergy Therapeutics, Hugo Boss, Boehringer Ingelheim, Mylan, Meda Pharmaceutical, Sanofi, Hollister Incorporated, Ionis Pharmaceuticals, DBV Technologies, TheraTogs, Allergenis, Circassia, ALK Abello | | SEGMENTS COVERED | Type, Product, Indication, Patient Type | | KEY MARKET OPPORTUNITIES | Growing prevalence of allergies, Increased adoption of sublingual immunotherapy, Expansion of personalized medicine approaches, Enhanced patient awareness and education, Investment in digital health solutions | | KEY MARKET DYNAMICS | Increasing prevalence of allergies, Growing awareness of immunotherapy, Technological advancements in treatments, Regulatory support and approval, Rising demand for personalized medicine | | COUNTRIES COVERED | UK | ## Frequently Asked Questions **Q: What is the current valuation of the UK Allergy Immunotherapy Market?** A: The market valuation was 217.91 USD Million in 2024. **Q: What is the projected market size for the UK Allergy Immunotherapy Market by 2035?** A: The market is projected to reach 587.28 USD Million by 2035. **Q: What is the expected CAGR for the UK Allergy Immunotherapy Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 9.43%. **Q: Which segments are included in the UK Allergy Immunotherapy Market by indication?** A: The market segments by indication include Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. **Q: What are the estimated values for Allergic Rhinitis in the UK Allergy Immunotherapy Market?** A: The estimated values for Allergic Rhinitis range from 65.0 to 175.0 USD Million. **Q: How does the market perform in terms of subcutaneous and sublingual immunotherapy?** A: Subcutaneous Immunotherapy is valued between 40.0 and 100.0 USD Million, while Sublingual Immunotherapy ranges from 50.0 to 150.0 USD Million. **Q: What are the projected values for food allergies in the UK Allergy Immunotherapy Market?** A: The projected values for Food Allergies range from 62.91 to 182.28 USD Million. **Q: Which age groups are targeted in the UK Allergy Immunotherapy Market?** A: The market segments by patient age group include Pediatric, Adult, Geriatric, and Adolescent. **Q: What is the value range for the Adult age group in the UK Allergy Immunotherapy Market?** A: The value range for the Adult age group is projected between 100.0 and 300.0 USD Million. **Q: Who are the key players in the UK Allergy Immunotherapy Market?** A: Key players include Allergopharma, ALK-Abello, Merck KGaA, Stallergenes Greer, and others. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-allergy-immunotherapy-market-56292*